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A novel anthropomorphic flow phantom for the quantitative
evaluation of prostate DCE-MRI acquisition techniques
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Abstract
A novel anthropomorphic flow phantom device has been developed which can be used for
quantitatively assessing the ability of MRI scanners to accurately measure signal /
concentration time-intensity curves (CTCs) associated with dynamic contrast-enhanced
(DCE) MRI. Modelling of the complex pharmacokinetics of contrast agents as they perfuse
through the tumour capillary network has shown great promise for cancer diagnosis and
therapy monitoring.

However, clinical adoption has been hindered by methodological

problems, resulting in a lack of consensus regarding the most appropriate acquisition and
modelling methodology to use and a consequent wide discrepancy in published data. A
heretofore overlooked source of such discrepancy may arise from measurement errors of
tumour CTCs deriving from the imaging pulse sequence itself, while the effects on the fidelity
of CTC measurement of using rapidly-accelerated sequences such as parallel imaging and
compressed sensing remain unknown.

The present work aimed to investigate these

features by developing a test device in which „ground truth‟ CTCs were generated and
presented to the MRI scanner for measurement, thereby allowing for an assessment of the
DCE-MRI protocol to accurately measure this curve-shape. The device comprised of a 4pump flow system wherein CTCs derived from prior patient prostate data were produced in
measurement chambers placed within the imaged volume.

The ground truth was

determined as the mean of repeat measurements using an MRI-independent, custom-built
optical imaging system. In DCE-MRI experiments, significant discrepancies between the
ground truth and measured CTCs were found for both tumorous and healthy tissuemimicking curve shapes. Pharmacokinetic modelling revealed errors in measured Ktrans, ve
and kep values of up to 42%, 31%, and 50% respectively, following a simple variation of the
parallel imaging factor and number of signal averages in the acquisition protocol The device
allows for the quantitative assessment and standardisation of DCE-MRI protocols (both
existing and emerging).
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Introduction
The technique of dynamic contrast-enhanced (DCE) MRI with pharmacokinetic (PK)
modelling of the contrast agent uptake curves has shown considerable potential as a
quantitative marker of tumour malignancy and also for monitoring of therapy. However, its
adoption into routine clinical practice has been hindered by uncertainties surrounding the
most appropriate or optimum acquisition protocol and also the choice of PK model to use to
analyse the measured uptake curves. This has resulted in a plethora of protocols and
processing methodologies being used in the published literature, with a commensurate wide
divergence in published data which has diminished the discriminative potential of the
technique.
In DCE-MRI a sequence of consecutive T1-weighted MR images are acquired as a bolus of
gadolinium-based contrast agent (CA) is administered to a patient, producing a signal timeintensity curve (STC) for each voxel, from which contrast time-intensity curves (CTCs) can
be derived (see Appendix 1 for more details).

The shape of CTCs is related to the

microvascular structure of the tissue being imaged. Tumour microvasculature has been
demonstrated to be important for prostate cancer (PCa) diagnosis, response assessment,
and treatment planning (Yang and Knopp, 2011).

Generally, when a tumour grows to

200 µm or greater, it induces angiogenesis (the formation of new blood vessels) through the
sprouting of capillaries from pre-existing micro-vessels (Battegay, 1995), which causes an
increase in microvasculature (Folkman, 1990). This microvasculature tends to be more
heterogeneously distributed and have higher permeability when compared to the
microvasculature of healthy tissue (Passe et al., 1997). However, a challenge for DCE-MRI
relates to the relatively low spatial resolution (millimetre scale) at which MR images are
acquired, whereas micro-vessels in the capillary bed have an average internal diameter of
approximately 8 m (Martini, 2012).

This discrepancy in scale means that the signal

measured from a single voxel is not actually a direct measure of microvasculature, but rather
a measure of bulk concentration, which is influenced by several physiological factors, such
as micro-vessel density, cellular density, and the volume of the extravascular extracellular
space.

Semi-quantitative phenomenological parameters can be extracted directly from the STCs,
such as the onset to enhancement, wash-in gradient, maximum intensity, wash-out gradient,
and integral area under gadolinium contrast concentration after 60 seconds.

These

parameters have shown efficacy for differentiating malignant from healthy prostate tissue.
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For example, using the wash-in rate Kim et al. reported an increase in sensitivity and
specificity from 65% to 96% and 60% to 82% respectively in the detection and localisation of
PCa, compared to T2-weighted imaging alone (Kim et al., 2005).

Although useful in

differentiating normal from malignant prostate tissue, the functional information provided by
this type of model free analysis is limited, since the enhancement curve is dependent on
multiple physiological factors. On the other hand PK modelling of CTC data offers the
prospect of extracting and quantifying sub-voxel functional physiological information, such as
the volume-transfer constant (Ktrans) and the fractional volume of the extravascular
extracellular space (ve), allowing for a more accurate elucidation of tumour biology. In the
literature, several models have been proposed for use in the PK analysis of prostate DCEMRI data, most commonly conventional compartmental models such as the Standard and
Extended Tofts models (Tofts and Kermode, 1991, Tofts et al., 1999), as well as more
complex models such as the Shutter Speed (Li et al., 2005) and Adiabatic Approximation of
Tissue Homogeneity (St Lawrence and Lee, 1998); however, to date, there is no consensus
as to which is most appropriate for modelling sub-voxel CA behaviour in prostate tissue.

The temporal resolution of data acquisition has been shown to affect the accuracy of derived
PK parameters, with some of the more complex models requiring very rapid acquisition
(Henderson et al., 1998); however, in previous DCE studies of the prostate that used PK
modelling, temporal resolutions varied widely from 2 to 30 s (Rosenkrantz et al., 2015). The
arterial input function (AIF), the concentration of CA as it enters the tissue of interest, is also
a vital component of most PK models, and any error in measuring or estimating the AIF will
result in an error in the derived PK parameters. Measurement of the AIF is particularly
sensitive to temporal resolution, since it is a rapidly-varying CTC, and as such its accurate
measurement requires fast acquisition, of the order of 1 s (Henderson et al., 1998).
Advances in phased array detector technology, which implement various forms of
accelerated imaging, such as k-t SENSitivity Encoding (SENSE) (Pruessmann et al., 1999),
SiMultaneous Acquisition of Spatial Harmonics (SMASH) (Sodickson and Manning, 1997),
and GeneRalized Autocalibrating Partially Parallel Acquisitions (GRAPPA) (Griswold et al.,
2002), faster gradient coils, coupled with novel acquisition techniques, such as compressed
sensing (Lustig et al., 2007), show potential to greatly improve temporal resolution without
sacrificing image quality, allowing for the use of more complete and accurate PK models.
However, there is always a trade-off between acquisition speed and image quality, and to
date a gold standard method to quantitatively evaluate this „trade-off‟ is lacking. This is
mainly related to difficulties associated with determining the accuracy of measured
parameters, since the actual parameters in the object of interest are generally unknown.
There is thus a need for a physical device to quantitatively and prospectively test these new
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DCE techniques in situ in the scanner, and various phantom designs have been proposed to
this end.

One such design type utilises the hollow fibres found commonly in commercial
haemodialysis cartridges to produce „leaky‟ phantom devices, which physically mimic
permeable microvasculature. Heilmann et al. demonstrated the usefulness of this type of
phantom design in the classification of the permeability characteristics for CAs with different
molecular weights (Heilmann et al., 2009). In a study by Mehrabian et al., a similar phantom
design was used to test an independent component analysis technique for separating the
AIF and extravascular space signals using the signal that is measured in the target tissue
(Mehrabian et al., 2011).

However, since these phantom designs physically mimic the

behaviour of blood vessels, the CTCs produced are dependent on the porosity and perfusion
conditions of the system and hence it is not possible to theoretically calculate actual
parameter values against which to check the accuracy of the PK modelling. Furthermore,
the inevitable retention of CA in the gel space surrounding the hollow fibres limits the use of
such devices for multiple experiments.

Other designs include „lesion‟ phantoms, which

produce an enhancement curve within single or multiple compartmentalised spaces. In a
study by Freed et al., a single 10 mm spherical measurement chamber was mounted into a
breast phantom, and the phantom‟s ability to produce measurable CTCs was demonstrated
(Freed et al., 2011). The behaviour of the system was characterised using a high spatial
resolution X-ray system, although its temporal resolution was poor (2.6 – 24.7 s).
Additionally, the MR data was acquired at a very low temporal resolution (79 s), making it
difficult to access the CTCs measured using MRI. Ledger et al. presented a phantom which
consisted of a 40 mm spherical object divided into four inter-linking compartments, for use in
quality assurance and the development of DCE-MRI breast protocols (Ledger et al., 2014).
Good repeatability was reported for MR measurements made in the phantom, however the
curves produced by the system were not independently verified or characterised by a
modality other than MRI, meaning that the system‟s utility was limited to the relative
comparison between MR measurements. A further limitation of the above-described studies
was that none allowed for measurements to be made in an environment which realistically
challenges prostate DCE-MR imaging by closely emulating conditions observed in vivo, in
terms of physical size, image complexity, and sparsity.

The aim of the current work was to develop an anthropomorphic phantom device in which
precisely and accurately known „ground truth‟ CTCs were generated and thus could be
presented to the MRI scanner for measurement, thereby allowing for a quantitative
assessment of the scanner‟s ability to accurately measure the contrast agent wash-in and
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wash-out curve-shapes.

The hypothesis under investigation was that measurement

inaccuracies in these curves-shapes, whether slowly or rapidly-varying, deriving from
features of the DCE imaging pulse sequence themselves, may contribute significantly to the
wide divergence in DCE PK modelling output parameter values in the published literature.

Methods
Phantom design
The phantom contained two measurement chambers, the geometry of which (illustrated in
Figure 1(a)) was optimised in a previous study using computational fluid dynamical
modelling to allow for optimal uniform distribution of liquids at low flow rates (Hariharan et al.,
2013). The 12 mm diameter of these chambers was selected specifically so that several
DCE imaging voxels, of a size typically used in prostate DCE, could be positioned within,
minimising any partial volume effects due to the chamber walls. These two measurement
chambers were set within a larger prostate-sized object (manufactured using a rapid
prototyping system) containing a further arrangement of chambers, as shown in Figure 1(b).
Liquid containing the Gd-DTPA CA (Multihance, Bracco, USA) was pumped into each
measurement chamber through the two inputs and subsequently flowed out through the
central output (Figure 1(a)) and then through the larger prostate „volume‟, before leaving via
a single waste output, as shown in Figure 1(b). This larger volume was designed to mimic
the enhancement profile typical of the entire prostate, imitating the reduction in sparsity in
the temporal domain observed in in vivo scans, which should facilitate the robust validation
of certain emerging techniques, such as compressed sensing (Lustig et al., 2007).

(a)

(b)
Figure 1: (a) Schematic representation of the geometry of the one measurement chamber‟s input/output

configuration, and (b) photographs of the final prostate-mimicking object (left: complete, and right: sectioned)
containing the two measurement chambers, with inputs into chambers 1 (red) and 2 (blue) highlighted.
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This prostate was set into a large custom-built anthropomorphic phantom device (shown in
various stages of construction in Figure 2; phantom size = 280(w) x 390(l) x 200(h) mm3).
Agar-based tissue mimic materials (TMMs) were used to mimic the T1 and T2 properties of
bone, muscle, fat, and bladder tissue (details of TMM composition are presented in Table 1).
Latex moulds were produced and used to shape certain components, such as the femur
bones and bladder.

Figure 2: (a–d) Photographs showing various stages during construction of the large anthropomorphic phantom,
with: (a) an initial layer of fat TMM; (b) a layer of muscle TMM (red dye used to differentiate from other TMMs); (c)
the prostate mimicking object in situ prior to surrounding TMM being deposited, as well as two „femur bones‟
composed of bone TMM; (d) deposition of a heterogeneously distributed fat / muscle layer; and (e) the final
phantom device. Dimensions: 280(w) x 390(l) x 200(h) mm3.

Table 1: Composition of TMMs used in construction of anthropomorphic phantom
Agar [wt. %]

Gd-DTPA [mM]

MnCl2 [mM]

NaCl [wt. %]

Benzalkonium
Chloride [wt. %]

Bone
Muscle

2.5
4.0

-

0.085
0.026

0.5
0.5

0.046
0.046

Fat
Bladder

2.7
3.0

0.35
-

-

0.5
0.5

0.046
0.046

Fluid pump system design and operation
A computer-controlled multi-pump system was designed to produce two simultaneous CTCs
within the two separate measurement chambers. The pump system consisted of four gear
pumps (Reglo-Z, ISMATEC, Switzerland), and was designed to produce CTCs by varying
the relative flow rates of two pumps feeding a given measurement chamber in parallel over
time, one pumping a lower baseline concentration, the other a higher concentration of the
CA (pumps 1 and 2 feeding measurement chamber 1, and pumps 3 and 4 feeding
measurement chamber 2, as illustrated in Figure 3). This configuration ensured a constant
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volumetric flow rate so that any potential flow-related artefacts would be constant across the
concentration range. The inlet tubing placement within the phantom was designed such
that, for imaging fields of view typical of DCE protocols, the inflowing liquid was driven to a
steady-state prior to entering the measurement chambers, thereby eliminating inflow
artefacts.

Concentrations of CA (0.15mM and 1.5mM) were selected to give a similar

relative peak enhancement to that observed in vivo. The flow rate produced by the pumps
was controlled by a time-varying voltage signal produced via a 12-bit analog output module
(USB-DA12-8A, ACCES, USA), controlled using custom-written in-house software. The fluid
from both pumps flowed through 8 m of 6.4 mm internal diameter (i.d.) tubing (Tygon-R,
Saint-Gobain, France) before mixing together via a „Y‟ connection, following which the fluid
travelled a further 1.2 m down a single 6.4 mm i.d. tube before bifurcating to two 3.2 mm i.d.
tubes and traveling into the phantom.

After passing through the mixing chambers and

prostate object the liquid is output to a waste container through a single 6.4 mm i.d. tube.

Figure 3: Schematic diagram of complete pump system (red and blue traces are representative of the change in
flow rate at each pump over time, with the overall flow-rate kept constant).

Contrast time-intensity curves
The physiological curves used in this study, mimicking tumour and healthy tissue, were
generated via the Tofts-Kety model based on PK parameters (Ktrans = 0.126 min-1 (healthy)
and 0.273 min-1 (tumorous) and ve = 0.292 (healthy) and 0.412 (tumorous)) taken from
patient prostate data from a previous study (Alonzi et al., 2010), as well as a model AIF
generated using the method and model parameter values reported by Parker et al. (Parker
et al., 2006), using code developed in MatLab (R2015b, MathWorks Inc., USA). For each
experiment, the CTCs consisted of a 10 s flush, 120 s of baseline flow, and a 300 s
physiological curve (representing either tumorous or healthy tissue).
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Characterising CTCs and establishing the optimal flow rate for the system
In order to characterise the response of the phantom system, and hence the actual shape of
the CTCs produced in the measurement chamber (the „ground truth‟) after the fluid has been
pumped through 11 m of tubing and several tubing connectors, an optical imaging system
was designed and set-up as shown in Figure 4. This optical imaging system was also used
to establish the threshold minimum flow rate, above which CTC curve-shape distortions were
minimised and uniform distribution of dye within the measurement chambers was achieved.

Figure 4: Schematic diagram of optical imaging system setup used to establish minimum flow rates and ground
truth measurements for the CTCs produced by the system.

In this system, a single measurement chamber was connected to two pumps, with the same
tubing configuration and lengths as for the main phantom device, and set within a custombuilt light-sealed enclosure. An endoscopic light source (Fujinon Eve Σ400, Fujifilm Corp,
Japan) was used in conjunction with a high resolution CMOS camera (Canon 50D, Canon
Inc, Japan) with a 4752 x 3168 array for detection, giving 4 x 4 µm2 pixels, and a temporal
resolution of 1 s. An ROI was defined across approximately the same spherical region of the
measurement chamber as used in the ROI analysis of the MR data. The temporal stability of
measurements made using the optical scanner was measured over a thirty-minute period by
imaging the chamber without liquid flow every second and calculating the variation in mean
signal over that period. Black dye was used as a CA surrogate in the system, which caused
a change in the measured intensity at different concentrations due to the attenuation of
incident photons. Imaging known concentrations of dye in the chamber across a range of
concentrations used for the CTC runs produced a calibration curve. The calibration curve
was fitted using a least squares method with a model adapted from the Lambert–Beer
equation, given as:

(1)
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where: y = dye concentration, x = average intensity measured over a region of interest
(ROI), and a, b , and c are constants derived from fitting the model to the calibration curve
data. Very good agreement was observed between the model and the calibration data (R2 =
0.998). The calibration curve was used to derive the black dye CTCs from the optical STCs,
which were subsequently converted to Gd CTCs (for comparison against the DCE-MRI data)
using:

(2)

where Cdye is the total concentration of dye, and CGd the total concentration of Gd, in the
measurement chamber, comprising of a proportional contribution from each reservoir, which
in turn depends on the relative flow rates of the pumps. CHdye and CHGd are respectively the
concentrations of dye and Gd used in reservoir one, the higher CA concentration reservoir;
and CLdye and CLGd are respectively the concentrations of dye and Gd used in reservoir two,
the lower CA concentration reservoir (see Appendix II for the full derivation of Equation [2]).
In order to establish the minimum flow rate for the system, full CTC runs of the tumorous
curve were measured at flow rates from 0.5 to 3.5 ml s-1, in 0.5 ml s-1 increments. Two
criteria were accessed when selecting the minimum threshold flow rate, namely: (i) how well
the measured curves fit those expected based on the pump voltage input (programmed),
assessed by calculating the percentage root mean square error (%RMSE) between the
programmed and measured CTCs (RMSE reported as a percentage of the overall
enhancement of the tumorous CTC); and (ii) the uniformity of CA distribution measured
within the chamber, calculated by subtracting a static image with no-flow from several
images with flow, taken from different experimental runs during the most rapidly changing
portion of the CTC (i.e. „wash-in‟ region on tumorous curve), with percentage uniformity
across the resultant images calculated. Once a minimum flow rate had been established,
five full CTC runs were measured for each curve (tumorous and healthy).

Intraclass

correlation coefficient (ICC) analysis was performed on the data in order to access the
repeatability of CTCs produced by the system, and the mean CTCs values taken as the
measured ground truth, for comparison with the MR data.

MRI measurements
To demonstrate the operation of the phantom, DCE-MRI data were acquired using a 3T
scanner (Achieva, Philips, Netherlands) and 32-channel phased array cardiac detector coil
(Philips, The Netherlands).

A 3D spoiled gradient echo imaging sequence with multi-
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transmit was used, with the following scan parameters: repetition time = 3.8 ms, echo time =
1.4 ms, flip angle (FA) = 10, matrix size = 224 x 224 x 80 mm3, spatial resolution = 1 x 1 x
4 mm3, and number of slices = 20. The parallel imaging factor (SENSE) and number of
signal averages (NSA) were varied to give temporal resolutions from 1.9 s to 21.4 s, as
shown in Table 2. Two manually-selected ROIs were used in the analysis of the data, each
containing 24 voxels and set within the respective measurement chamber. The relaxivity (r1)
of the CA in aqueous solution was calculated using a multi-FA approach (FA = 2 to 20 in
increments of 2) by imaging a phantom containing vials with known concentrations of CA.
This phantom was deliberately kept small (60 x 60 x 120 mm 3), and positioned at the centre
of the bore in order to minimise any effects of B1 inhomogeneity on the measurements.
Table 2: MRI scan parameters, adjusted to achieve temporal resolutions from 1.9 s to 21.4 s.
Scan Number

R-factor (AP / FH)

NSA

Temporal Resolution [s]

1
2

1.8 / 2
1.4 / 1.6

1
1

1.9
3.4

3

1.2 / 1.4

1

5

4
5
6

1
1
1

1
2
3

7.1
14.3
21.4

Data analysis
The AIF was generated using the method proposed by Parker et al. (Parker et al., 2006) with
code developed in MatLab at temporal resolutions matching those used in the optical and
MR studies, to simulate measurement of the AIF, and was then subsequently used in the
analysis of all optical and MR data. All PK modelling was performed using the DCEMRI.jl
toolkit (Smith et al., 2015). The standard Tofts-Kety model was used to derive Ktrans, ve, and
kep values for the ground truth CTCs (i.e. as measured in the optical experiments) and the
MRI-measured CTCs, and the percentage differences calculated. The optical data were
analysed using a ROI approach (i.e. PK parameters were derived from single mean CTCs,
averaged from multiple pixel measurements), and the MR data using both ROI and voxelwise methods (i.e. PK parameters calculated for multiple CTCs taken from each voxel within
the ROI, and mean PK parameter values and standard deviations calculated). The flow
diagram presented in Figure 5 visually illustrates the steps that were implemented in the
acquisition and analysis of the data.
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Figure 5: Flow diagram illustrating the steps implemented in the analysis of the DCE-MRI and optical data.

Results
Phantom construction
Measurement chambers with a wall thickness of 0.3 mm were produced using an Eden 250
3D-printing system (Stratasys, USA) and VeroClear polymer (FullCure-GD810, Stratasys,
USA). Agar-based tissue mimic materials were produced which closely approximated the T1
and T2 properties of bone, muscle, fat, and bladder tissue (de Bazelaire et al., 2004).
Optical experiments
The temporal stability of measurements made using the optical scanner was found to vary
by 0.4% over a 30-minute period. The %RMSE values between the optically-measured
and programmed CTCs were lowest (< 4%) with flow rates  1.5 ml s-1, with no further
decrease in the %RMSE values observed at flow rates greater than 1.5 ml s-1, as shown in
Figure 6. At a flow rate of 1.5 ml s-1 the uniformity of CA distribution across the chambers
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was measured to be 96%, with uniformity decreasing at lower flow rates, and not changing
significantly at flow rates higher than this. This analysis revealed a clear threshold minimum
flow rate for the phantom setup of 1.5 ml s -1, and as such this flow rate was used for all
subsequent experiments.

Very good correlation was observed between the five

consecutively measured CTCs for both curve shapes (tumorous and healthy) as illustrated in
Figure 7, with high ICC values of 0.996 and 0.998 for healthy and tumorous CTCs
respectively. Average values from each of the five measured CTCs were converted to GdDTPA concentration, and used as the measured ground truth CTCs in subsequent MRI
experiments.

PK parameters values were also calculated from each of the optically-

measured CTCs, with the mean values taken as the ground truths. Ground truth Ktrans
values were measured to be 0.123 ± 0.001 min-1 and 0.233 ± 0.002 min-1, and ve 0.355 ±
0.001 and 0.461 ± 0.002, for healthy and tumorous CTCs respectively (errors are given by
the standard deviation across repeated optical-measurements).

(a)

(b)
Figure 6: Plots showing: (a) the % root mean square error (%RMSE) values calculated between the
programmed and optically-measured CTCs at different flow rates (presented as a percentage of the overall

programmed CTCs amplitude); and (b) the programmed and optically-measured ground truth tumorous CTCs
(measured with 1.5 ml s-1 flow rate).

(a)

(b)

Figure 7: Plots showing five repeated measurements of the (a) tumorous and (b) healthy CTCs used in this
study, using the optical imaging system at 1.5 ml s-1 flow rate.
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MRI Experiments
Initial scans of the large anthropomorphic phantom show similar visual appearance to in vivo
patient prostate scans, as shown in Figure 8. Figure 9 shows preliminary data comparing
the CTCs derived from the MR data with those from the ground truths. All protocols (with the
exception of the 5 s temporal resolution protocol) measured the healthy-shaped CTC with R2
> 0.95, however only two protocols measured the tumorous-shaped CTC with an R2 > 0.95
(7.1 and 14.3 s). Ktrans, ve and kep values derived from the MR data were found to differ from
the ground truths by up to 42%, 31%, and 50% respectively; details of the specific PK
parameter errors as a function of the temporal resolution used for the DCE acquisitions are
presented in Figure 10, for both a voxel-wise and ROI analysis of the data. PK parameters
derived using these two different methods (voxel-wise versus ROI) differed by < 4%, with all
PK parameter values derived using the ROI method within the standard deviations of those
derived using the voxel-wise approach.
tumorous and healthy K

trans

The lowest errors in the measurement of both

, ve and kep values occurred using the 7.1-, 21.4-, and 1.9-

second temporal resolution protocols respectively.

Figure 8: Axial T1-weighted image of the anthropomorphic phantom with the „prostate‟ and measurement
chambers highlighted. Regions mimicking subcutaneous fat, muscle, and bone are visible
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Figure 9: Plots presenting tumorous and healthy CTCs derived from DCE-MRI data at 1.9 to 21.4 s temporal
resolutions, compared with the ground truths derived from optical scanner data.
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(a)

(b)

(c)

Figure 10: Percentage errors in (a) Ktrans, (b) ve, and (c) kep values derived from the DCE-MRI data using the
Tofts-Kety model. Values shown for both a voxel-wise and ROI analysis of the data. Error bars shown for
voxel-wise results taken from the standard deviation in the data.

Discussion
There is currently a lack of standardisation of prostate DCE-MRI image acquisition protocols,
particularly in relation to the trade-off which must be made between spatial and temporal
resolution, with studies in the prostate alternatively giving preference to either spatial
resolution (McClure et al., 2012, Costa et al., 2013) or temporal resolution (Vos et al., 2013,
Chen et al., 2012). The European Society of Urogenital Radiology presented guidelines
(Barentsz et al., 2012) which recommend a temporal resolution of ≤ 15 s and spatial
resolution of ≤ 0.7 x 0.7 x 4 mm3; however, there is growing consensus that temporal
resolutions much lower than 15 s are required when more complex PK models are used to
analyse the data (Henderson et al., 1998). However, the effect on measurement accuracy of
pushing the temporal resolution to these values remains unclear, and to date it has not been
possible to quantitatively assess measurement errors deriving from acquisition protocolrelated factors. It has rather been assumed that such protocols accurately measure slowly-
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changing CTCs, such as those in healthy tissue and most tumours, whereas only rapidlychanging tumour CTCs, and AIFs in particular, pose a problem for MRI measurement.
However, the results presented herein using the novel phantom design demonstrate the
significant influence the acquisition protocol has on the measured shape of even slowlychanging CTCs. Given the ability to generate and characterise any arbitrary CTC-shape, it
was possible to quantify errors in PK output parameter estimation deriving exclusively from
the DCE acquisition protocol. Using specific Ktrans and ve values (taken from prior prostate
patient studies) to generate CTCs, using the optical imaging system to determine the actual
CTCs arriving in the phantom, and finally performing a PK analysis on the opticallymeasured CTCs (and hence re-deriving the actual „ground truth‟ Ktrans and ve values that
would give rise to this curve-shape); differences between the ground truth PK parameter
values and those derived from the MR-measured CTCs could be used to quantify errors in
the DCE acquisition protocol.

Key to this determination of accuracy was a precise and accurate knowledge of the ground
truth CTC presented to the MRI scanner for measurement. In attempts to characterise the
CTCs produced by their phantom systems, previous studies have used repeated MR
measurements (Casas et al., 2014), prediction models (Driscoll et al., 2011, Ebrahimi et al.,
2010), and X-ray measurements (Freed et al., 2011); however, these system designs do not
allow for a determination of the ground truth against which DCE-MRI measurements can be
compared. In the current study the ground truth CTCs were independently determined using
a high spatial and temporal resolution, calibrated optical imaging system. The use of a
„ground truth‟ descriptor for the CTCs in this context was considered reasonable due to the
low measurement error associated with the optical imaging system (±0.4% measurement
accuracy; ICC > 0.996 for consecutive runs, both tumorous and healthy CTCs).
Concentration values were derived via a calibration curve, the data for which was acquired
by imaging known concentrations of black dye with no flow; however, the same known
concentrations were also imaged with flow of 1.5ml s-1, with no measurable differences
observed between the two datasets. Differences between the programmed and opticallymeasured CTCs translated to an 18% maximum difference between the programmed and
optically-measured ground truth PK parameters values, for the CTCs used in the study.
However, the resultant ground truth PK parameters values were still well within the range of
patient-derived values for tumorous and healthy prostate tissue reported in the literature
(Alonzi et al., 2010). Furthermore, repeat optical experiments demonstrated the ability of the
phantom system to precisely reproduce contrast curves with these PK parameter values,
with low standard deviations of <1.2% recorded for all optically-measured ground truth PK
parameter values.
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The choice of flow rate used in the phantom device struck a balance between minimising
discrepancies between the programmed and optically-measured CTCs (which imposed a
lower limit on the flow rate that could be used) and reducing the potential for flow artefacts in
the MR images (which mitigated against using very high flow rates). Discrepancies between
the programmed and measured CTCs occur at lower flow rates due to two principal factors:
(i) excessive longitudinal mixing along the length of the tubing caused by diffusional and
turbulent flow effects which adversely affected the shape of the CTCs produced; and (ii) an
incomplete flushing of the solution within the entire volume of the measurement chamber at
each time-point within a DCE run, resulting in undesired dye (and hence MR contrast agent)
concentration variations within the chambers. This latter effect was noted in an earlier study
involving computational fluid dynamics of flow profiles in measurement chambers of similar
design to that used herein (Hariharan et al., 2013). In the current study, a flow rate of
1.5 ml s-1 was found to be sufficient to eliminate this effect, as determined by the highlyuniform (> 96%) dye distribution measured within the measurement chambers. This flow
rate also marked the threshold at which the %RMSE between the programmed and
measured CTCs was minimised (< 4%).

There were minor differences between the two modalities (optical and MRI) in where and
how the signal was measured; for example, the ROI used for the optical experiments
encompassed data from approximately 90% of the measurement chamber‟s volume,
whereas with the MRI experiments the ROI analysis was performed on voxels measured in a
4 mm slice taken through the centre of the chambers. However, since the phantom system
provided highly-uniform distribution of CA within the measurement chambers at the flow rate
used, one may assume that the concentration measured at a particular voxel in the MR data
is representative of the overall concentration within the chamber, and since the optical
experiments also provide a measure of the overall CA concentration within the measurement
chamber, direct comparison between the two modalities was possible.

An anthropomorphic phantom design was used with an internal complexity and physical
dimensions sufficient to present a clinically-realistic challenge to the image acquisition
protocols under test, with a specific emphasis herein on prostate imaging although the
principal is valid for other body areas.

Thus, protocols developed and validated using the

phantom can be easily translated to patient studies in the clinic. A visual comparison of the
CTCs presented in Figure 9 shows discrepancies between the measured and ground truth
curve-shapes, and this is reflected in the calculated R2 values.

An apparent bias was

observed in the MR-measured curves in the form of an underestimation of the concentration
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values in the ~ 20 – 100 s time range (see Figure 9), the source of which remains the
subject of future work. Of the acquisition protocols tested, it was found that Ktrans was most
accurately measured using a protocol with a temporal resolution of 7.1 s. As the parallelimaging factor was increased with resultant improvement in temporal resolution, the
accuracy of Ktrans measurements decreased by up to 15%, which may be related to
decreased SNR in the images, although other parallel imaging-related factors may also have
contributed to these increased errors.

Furthermore, as the NSA was increased in

subsequent experiments, causing a deterioration in temporal resolution, the accuracy of the
measured Ktrans values also decreased by up to 31%, as one would expect due to the
reduced number of sampling points leading to a loss of fidelity in the shape of the measured
CTCs, particularly rapidly changing portions of the curves such as the initial wash-in (on
which Ktrans is strongly dependant), as well as the resampled AIF used for the PK modelling.
ve was measured with the lowest error at 21.4 s temporal resolution, possibly due to more
accurate measurement of the CTCs‟ wash-out section for which ve is most sensitive. Errors
in measured kep were lowest using the 1.9 s temporal resolution protocol, and increased at
temporal resolutions > 1.9 s. These preliminary data highlight the need to further refine
acquisition protocols to identify the source of and hence to reduce these errors

These data demonstrate the critical dependence of the accuracy of PK output parameter
values on the quality of the data inputted to the models, whether that be adequate temporal
sampling of the uptake curves, or adequate data quality to ensure faithful fitting of the model.
It should be noted that the use of inappropriate PK models for specific tissue and tumour
types also likely contributes to discrepancies in the published literature (Sourbron and
Buckley, 2012), and here again the current phantom device could be of use, for example in
exploring the relationship between SNR and temporal resolution on the modelling accuracy
for increasingly complex PK models.

In the preliminary data presented in this study, no B1 corrections were made, however it is
likely that any inhomogeneity present may have contributed to errors. Other issues, such as
inadequate spoiling, B0 inhomogeneity, and off-resonance effects, may also have
contributed to the errors in the MR-measurements.

The anthropomorphic nature of the

phantom will facilitate further investigation of these deviations in ideal performance of the
spoiled gradient echo imaging sequence, and are the focus of future work. Potential further
errors arising from the use of rapidly-accelerated techniques such as parallel imaging, zoom
imaging, and compressed sensing remain to be tested, and are the current focus of on-going
work in this area. This work nevertheless further demonstrates the difficulties in performing
quantitative measurements using what is substantially a qualitative instrument, that is, a
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clinical MRI scanner. Precise and accurate knowledge of the ground truth CTC values in the
phantom design presented herein, absent in other phantom designs, facilitates a more
quantitative approach to DCE-MRI by providing a test-bed on which new and existing
acquisition protocols can be quantitatively assessed.

Conclusions
The development of a novel dynamic anthropomorphic prostate phantom test device is
described, and its use in quantitatively determining the measurement accuracy of several
DCE-MRI acquisition protocols is demonstrated. The device is capable of simultaneously
producing two distinct, accurate, and reproducible CTCs representative of those observed in
DCE-MRI data of the prostate within two separate measurable regions. The programmed
shape of the CTCs produced by the system can easily be modified to simulate any shape
CTC, including tumour-mimicking and AIFs. Ground truth CTCs produced within the
phantom‟s measurement chambers were precisely and accurately determined using a
custom-built calibrated optical imaging system, which had high temporal and spatial
resolution. Errors in Ktrans, ve and kep values of up to 42%, 31%, and 50% respectively were
recorded with varying temporal resolution. These results demonstrate heretofore
unappreciated yet significant errors introduced by standard DCE acquisition protocols into
derived PK output parameter values. The phantom device provides a system on which new
DCE acquisition protocols can be accurately validated, for example those using highly
accelerated acquisition schemes such as compressed sensing.

Acknowledgments
This work is funded by Irish Cancer Society Research Scholarship CRS13KNI, supported by
the Movember Foundation. The authors would like to thanks staff at the CAMI and Vanderbilt
University Institute of Imaging Science MRI centres for assistance with scanner access, Dr
Sean Cournane for assistance with the ground truth measurements, and Prof Martin Hegner
for his assistance with the 3D printing of the prostate structure. One of the authors (SK) also
acknowledges a “Young Investigator Grant” from the Irish Association of Physicists in
Medicine.

19

Appendix I: Conversion of DCE-MRI STCs to CTCs
DCE-MRI STCs can be converted from signal to T1 values using the signal equation for a
spoiled gradient echo sequence:

(

)

(

)

(

(A.1.)

)
(

)

where S(x,t) is the signal as a function of space x and time t, θ is the flip angle, and TR is the
repetition time.

decay was ignored in our study, on the assumption that the echo time was

much shorter than

. T1 values can then subsequently be converted into [CA] via:

(A.2.)

where [CA] is the concentration of CA (mM), T1 is the measured T1 value at a given timepoint, T10 is the native T1 (i.e. the T1 of water in the case of our study), and r1 is the relaxivity
of the CA (mM-1s-1).

Appendix II: Derivation of relationship between dye and Gd concentrations
Below we derive a linear relationship between the dye and Gd concentrations. We assume
that the pumps perform the same across all experiments. Since the concentration of dye in
the chamber is controlled by varying the relative flow rates of two pumps in parallel, one
pumping the higher concentration of CA, the other the lower, we can model the contribution
from each pump to the overall concentration of CA in the chamber using the following:

(B.1.)
(B.2.)

where Cdye is the concentration of dye in the measurement chamber and CGd is the
concentration of Gd in measurement chamber. CHdye and CHGd are respectively the
concentrations of dye and Gd used in reservoir one, the higher CA concentration; and CLdye
and CLGd are respectively the concentrations of dye and Gd used in reservoir two, the lower
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CA concentrations. F1 and F2 give the normalised flow rate for pumps one and two
respectively. Since F1 and F2 are varied relative to one another across the full dynamic range
of the pumps, we have
(B.3.)

Substituting Equation (B.3.) into Equations (B.1.) and (B.2.) and rearranging gives
(
(

)
)

(B.4.)
(B.5.)

Combining Equations (B.4.) and (B.5.), one can then easily derive

(B.6.)

Equation (B.6.) provides a general model for the conversion of measured dye concentration
to Gd concentration, which is only dependent on the reservoir concentrations used, which
are constant.
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